Acadian Asset Management
SLN

Acadian Asset Management’s Silence Therapeutics SLN Stock Holding History

Acadian Asset Management’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$129K Buy
11,836
+7,018
+146% +$49.4K ﹤0.01% 1709
2026
Q1 		$25K Buy
+4,818
New +$26.5K ﹤0.01% 1931
2025
Q4 		– Sell
-4,218
Closed -$21K – 2110
2025
Q3 		$21K Buy
+4,218
New +$23.4K ﹤0.01% 1768
2025
Q2 		– Sell
-12,153
Closed -$34K – 1815
2025
Q1 		$34K Sell
12,153
-7,314
-38% -$35.7K ﹤0.01% 1483
2024
Q4 		$133K Buy
+19,467
New +$251K ﹤0.01% 1320

Other funds holding SLN

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Acadian Asset Management's SLN Position: Q2 2026 in Review

Acadian Asset Management increased its Silence Therapeutics (SLN) stake by 146% in Q2 2026, buying an estimated $49.4K and bringing the position to 11,836 shares worth $129K. The position accounts for ﹤0.01% of the portfolio, ranked #1709.

Acadian Asset Management first reported a position in SLN in Q4 2024 and has held it in 5 quarters since. The position peaked at $133K in Q4 2024. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • Acadian Asset Management held 11,836 shares of Silence Therapeutics worth $129K as of Q2 2026.
  • Acadian Asset Management bought 7,018 Silence Therapeutics shares in Q2 2026, an estimated $49.4K.
  • Silence Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1709 holding.
  • Acadian Asset Management first reported a position in Silence Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Acadian Asset Management's Silence Therapeutics position peaked at $133K in Q4 2024.
  • 72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.